Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides : providing a therapeutic option for all Huntington disease patients. / Skotte, Niels H; Southwell, Amber L; Østergaard, Michael E; Carroll, Jeffrey B; Warby, Simon C; Doty, Crystal N; Petoukhov, Eugenia; Vaid, Kuljeet; Kordasiewicz, Holly; Watt, Andrew T; Freier, Susan M; Hung, Gene; Seth, Punit P; Bennett, C Frank; Swayze, Eric E; Hayden, Michael R.

In: PLOS ONE, Vol. 9, No. 9, 2014, p. e107434.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Skotte, NH, Southwell, AL, Østergaard, ME, Carroll, JB, Warby, SC, Doty, CN, Petoukhov, E, Vaid, K, Kordasiewicz, H, Watt, AT, Freier, SM, Hung, G, Seth, PP, Bennett, CF, Swayze, EE & Hayden, MR 2014, 'Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients', PLOS ONE, vol. 9, no. 9, pp. e107434. https://doi.org/10.1371/journal.pone.0107434

APA

Skotte, N. H., Southwell, A. L., Østergaard, M. E., Carroll, J. B., Warby, S. C., Doty, C. N., Petoukhov, E., Vaid, K., Kordasiewicz, H., Watt, A. T., Freier, S. M., Hung, G., Seth, P. P., Bennett, C. F., Swayze, E. E., & Hayden, M. R. (2014). Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLOS ONE, 9(9), e107434. https://doi.org/10.1371/journal.pone.0107434

Vancouver

Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLOS ONE. 2014;9(9):e107434. https://doi.org/10.1371/journal.pone.0107434

Author

Skotte, Niels H ; Southwell, Amber L ; Østergaard, Michael E ; Carroll, Jeffrey B ; Warby, Simon C ; Doty, Crystal N ; Petoukhov, Eugenia ; Vaid, Kuljeet ; Kordasiewicz, Holly ; Watt, Andrew T ; Freier, Susan M ; Hung, Gene ; Seth, Punit P ; Bennett, C Frank ; Swayze, Eric E ; Hayden, Michael R. / Allele-specific suppression of mutant huntingtin using antisense oligonucleotides : providing a therapeutic option for all Huntington disease patients. In: PLOS ONE. 2014 ; Vol. 9, No. 9. pp. e107434.

Bibtex

@article{a3634529896448a8aeecb1b6fa78a81b,
title = "Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients",
abstract = "Huntington disease (HD) is an inherited, fatal neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. The mutant protein causes neuronal dysfunction and degeneration resulting in motor dysfunction, cognitive decline, and psychiatric disturbances. Currently, there is no disease altering treatment, and symptomatic therapy has limited benefit. The pathogenesis of HD is complicated and multiple pathways are compromised. Addressing the problem at its genetic root by suppressing mutant huntingtin expression is a promising therapeutic strategy for HD. We have developed and evaluated antisense oligonucleotides (ASOs) targeting single nucleotide polymorphisms that are significantly enriched on HD alleles (HD-SNPs). We describe our structure-activity relationship studies for ASO design and find that adjusting the SNP position within the gap, chemical modifications of the wings, and shortening the unmodified gap are critical for potent, specific, and well tolerated silencing of mutant huntingtin. Finally, we show that using two distinct ASO drugs targeting the two allelic variants of an HD-SNP could provide a therapeutic option for all persons with HD; allele-specifically for roughly half, and non-specifically for the remainder.",
author = "Skotte, {Niels H} and Southwell, {Amber L} and {\O}stergaard, {Michael E} and Carroll, {Jeffrey B} and Warby, {Simon C} and Doty, {Crystal N} and Eugenia Petoukhov and Kuljeet Vaid and Holly Kordasiewicz and Watt, {Andrew T} and Freier, {Susan M} and Gene Hung and Seth, {Punit P} and Bennett, {C Frank} and Swayze, {Eric E} and Hayden, {Michael R}",
year = "2014",
doi = "10.1371/journal.pone.0107434",
language = "English",
volume = "9",
pages = "e107434",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

RIS

TY - JOUR

T1 - Allele-specific suppression of mutant huntingtin using antisense oligonucleotides

T2 - providing a therapeutic option for all Huntington disease patients

AU - Skotte, Niels H

AU - Southwell, Amber L

AU - Østergaard, Michael E

AU - Carroll, Jeffrey B

AU - Warby, Simon C

AU - Doty, Crystal N

AU - Petoukhov, Eugenia

AU - Vaid, Kuljeet

AU - Kordasiewicz, Holly

AU - Watt, Andrew T

AU - Freier, Susan M

AU - Hung, Gene

AU - Seth, Punit P

AU - Bennett, C Frank

AU - Swayze, Eric E

AU - Hayden, Michael R

PY - 2014

Y1 - 2014

N2 - Huntington disease (HD) is an inherited, fatal neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. The mutant protein causes neuronal dysfunction and degeneration resulting in motor dysfunction, cognitive decline, and psychiatric disturbances. Currently, there is no disease altering treatment, and symptomatic therapy has limited benefit. The pathogenesis of HD is complicated and multiple pathways are compromised. Addressing the problem at its genetic root by suppressing mutant huntingtin expression is a promising therapeutic strategy for HD. We have developed and evaluated antisense oligonucleotides (ASOs) targeting single nucleotide polymorphisms that are significantly enriched on HD alleles (HD-SNPs). We describe our structure-activity relationship studies for ASO design and find that adjusting the SNP position within the gap, chemical modifications of the wings, and shortening the unmodified gap are critical for potent, specific, and well tolerated silencing of mutant huntingtin. Finally, we show that using two distinct ASO drugs targeting the two allelic variants of an HD-SNP could provide a therapeutic option for all persons with HD; allele-specifically for roughly half, and non-specifically for the remainder.

AB - Huntington disease (HD) is an inherited, fatal neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. The mutant protein causes neuronal dysfunction and degeneration resulting in motor dysfunction, cognitive decline, and psychiatric disturbances. Currently, there is no disease altering treatment, and symptomatic therapy has limited benefit. The pathogenesis of HD is complicated and multiple pathways are compromised. Addressing the problem at its genetic root by suppressing mutant huntingtin expression is a promising therapeutic strategy for HD. We have developed and evaluated antisense oligonucleotides (ASOs) targeting single nucleotide polymorphisms that are significantly enriched on HD alleles (HD-SNPs). We describe our structure-activity relationship studies for ASO design and find that adjusting the SNP position within the gap, chemical modifications of the wings, and shortening the unmodified gap are critical for potent, specific, and well tolerated silencing of mutant huntingtin. Finally, we show that using two distinct ASO drugs targeting the two allelic variants of an HD-SNP could provide a therapeutic option for all persons with HD; allele-specifically for roughly half, and non-specifically for the remainder.

U2 - 10.1371/journal.pone.0107434

DO - 10.1371/journal.pone.0107434

M3 - Journal article

C2 - 25207939

VL - 9

SP - e107434

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 9

ER -

ID: 153451149